Opioid prescription by gynecologic oncologists: An analysis of Medicare Part D claims

被引:1
|
作者
Samuel, David [1 ,2 ]
Nevadunsky, Nicole S. [2 ,3 ,4 ]
Miller, Devin T. [2 ,3 ]
Isani, Sara [2 ,3 ,4 ]
Kuo, Dennis Y. S. [2 ,3 ,4 ]
Gressel, Gregory M. [2 ,3 ,4 ]
机构
[1] Montefiore Med Ctr, Dept Obstet & Gynecol & Womens Hlth, 1300 Morris Pk Ave,Block Bldg Rm 628, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, 1300 Morris Pk Ave,Block Bldg Rm 628, Bronx, NY 10461 USA
[3] Montefiore Med Ctr, Div Gynecol Oncol, Dept Obstet & Gynecol & Womens Hlth, Bronx, NY USA
[4] Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY USA
关键词
Center for Medicaid and Medicare Services; Gynecologic oncology; Medicare Part D; Opioid; Opioid claim; Opioid epidemic; Opioid prescription; Prescriber demographics; Palliative care;
D O I
10.1016/j.currproblcancer.2020.100655
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of opioids across all specialties has increased greatly over the last 2 decades and along with it, opioid misuse, overdose and death. The contribution of opioids prescribed for gynecologic cancers to this problem is unknown. Data from other surgical specialties show prescriber factors including gender, geographic location, board certification, experience, and fellowship training influence opioid prescribing. To characterize national-level opioid prescription patterns among gynecologic oncologists treating Medicare beneficiaries. The Centers for Medicare and Medicaid Services database was used to access Medicare Part D opioid claims prescribed by gynecologic oncologists in 2016. Prescription and prescriber characteristics were recorded including medication type, prescription length, number of claims, and total day supply. Region of practice was determined according to the US Census Bureau Regions. Board certification data were obtained from American Board of Obstetrics and Gynecology website. Bivariate statistical analysis and linear regression modeling were performed using Stata version 14.2. In 2016, 494 board-certified US gynecologic oncologists wrote 24,716 opioid prescriptions for a total 267,824 days of treatment (median 8 [interquartile range {IQR} 6, 11] prescribed days per claim). Gynecologic oncologists had a median of 33 opioid claims (IQR 18, 64). Male physicians had significantly more opioid prescription claims than females ( P < 0.01) including after adjustment for differences in years of experience. There was no difference in prescribed days per claim between male and female physicians. Physicians in the South had the greatest number of opioid prescription claims and significantly more than physicians in all other regions ( P 0.01). Gynecologic oncologists who were board certified for 15 years had a greater number of median opioid claims (28 IQR 16, 50) than those with < 5 years since board certification (22 IQR 15, 38) ( P = 0.04). Physicians who were board certified in palliative care (n = 19) had significantly more opioids claims (median 40; IQR 18, 91) than those without (median 32; IQR 18, 64) ( P < 0.01). In 2016, there were gender-based, regional, and experience-related variations in opioid prescribing by providers caring for Medicare-insured patients. (c) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Analysis of psychiatrists' prescription of opioid, benzodiazepine, and buprenorphine in Medicare Part D in the United States
    Pan, Kevin
    Silver, Shawgi
    Davis, Charles
    TRENDS IN PSYCHIATRY AND PSYCHOTHERAPY, 2020, 42 (01) : 48 - 54
  • [2] Annual Trends in Medicare Part D Prescription Claims for Dupilumab 2017 to 2019
    Munawar, Leena
    Oulee, Aislyn
    Norden, Alexandra
    Thyssen, Jacob P.
    Wu, Jashin J.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2022, 21 (10) : 1138 - 1139
  • [3] Trends in Medicare Part D prescription claims for biologic and nonbiologic immunosuppressive medications by dermatologists
    Gronbeck, Christian
    Feng, Paula W.
    Feng, Hao
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (03) : 848 - 851
  • [4] Annual Trends in Medicare Part D Prescription Claims for Vismodegib, 2013-2018
    Gronbeck, Christian
    Feng, Hao
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (06) : 1356 - 1359
  • [5] The opioid prescribing practices of surgeons: A comprehensive review of the 2015 claims to Medicare Part D
    Khalid, Syed I.
    Kelly, Ryan
    Khalid, Ridha
    Wu, Rita
    Ni, Amilia Y.
    Adogwa, Owoicho
    Cheng, Joseph
    SURGERY OPEN SCIENCE, 2020, 2 (02) : 96 - 100
  • [6] An examination of opioid prescription for Medicare Part D patients among family practice prescribers
    Pan, Kevin
    Blankley, Alan, I
    Hughes, Peter J.
    FAMILY PRACTICE, 2019, 36 (04) : 467 - 472
  • [7] PRESCRIPTION OPIOID DISPENSINGS IN MEDICARE PART D IN 2020 BY US REGION AND PRESCRIBER TYPE
    Upadhyay, R.
    Kogut, S.
    VALUE IN HEALTH, 2024, 27 (06) : S242 - S242
  • [8] Opioid Prescribing Practices of Neurosurgeons: Analysis of Medicare Part D
    Khalid, Syed I.
    Adogwa, Owoicho
    Lilly, Daniel T.
    Desai, Shyam A.
    Vuong, Victoria D.
    Mehta, Ankit I.
    Cheng, Joseph
    WORLD NEUROSURGERY, 2018, 112 : E31 - E38
  • [9] Where are the medicare Part D claims data?
    Stuart, Bruce
    ANNALS OF INTERNAL MEDICINE, 2008, 148 (03) : 239 - 240
  • [10] Opioid Prescribing Patterns Among Generalists, Radiation Oncologists, and All Oncologists for Medicare Part D Beneficiaries from 2013-2017
    Agarwal, A.
    Roberts, A.
    Dusetzina, S. B.
    Royce, T. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E384 - E385